WO2026077396A1 - Traitement du cancer pharmacorésistant à base de conjugué anticorps-médicament anti-ror1 - Google Patents
Traitement du cancer pharmacorésistant à base de conjugué anticorps-médicament anti-ror1Info
- Publication number
- WO2026077396A1 WO2026077396A1 PCT/CN2025/126547 CN2025126547W WO2026077396A1 WO 2026077396 A1 WO2026077396 A1 WO 2026077396A1 CN 2025126547 W CN2025126547 W CN 2025126547W WO 2026077396 A1 WO2026077396 A1 WO 2026077396A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- variable region
- chain variable
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un anticorps anti-ROR1 humain, un conjugué anticorps-médicament comprenant l'anticorps anti-ROR1 humain, et utilisation pour traiter le cancer pharmacorésistant.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411410175.X | 2024-10-10 | ||
| CN202411410175 | 2024-10-10 | ||
| CN202510417023.0 | 2025-04-03 | ||
| CN202510417023 | 2025-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2026077396A1 true WO2026077396A1 (fr) | 2026-04-16 |
Family
ID=99438365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2025/126547 Pending WO2026077396A1 (fr) | 2024-10-10 | 2025-10-09 | Traitement du cancer pharmacorésistant à base de conjugué anticorps-médicament anti-ror1 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2026077396A1 (fr) |
-
2025
- 2025-10-09 WO PCT/CN2025/126547 patent/WO2026077396A1/fr active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7704815B2 (ja) | Ｂｃｍａに対する結合分子及びその使用 | |
| JP7427605B2 (ja) | 癌に対する三重特異性結合分子及びその使用 | |
| US8933202B2 (en) | AXL antibodies | |
| CN103328505B (zh) | 非拮抗性egfr结合分子及其免疫偶联物 | |
| JP2021101707A (ja) | 抗Ａｘｌアンタゴニスト抗体 | |
| KR102458196B1 (ko) | 항-axl 길항성 항체 | |
| US20240299574A1 (en) | Antibodies to pmel17 and conjugates thereof | |
| EP4470570A1 (fr) | Conjugué anticorps-médicament anti-her3 et son utilisation | |
| TW202442681A (zh) | 抗ror1抗體及其藥物偶聯物 | |
| EP2270053A1 (fr) | Anticorps AXL humanisés | |
| JP2024515266A (ja) | 抗ｃ－ＭＥＴ抗体及び抗体薬物複合体 | |
| AU2021255711A1 (en) | Diels-alder conjugation methods | |
| CN118791622A (zh) | 抗ror1抗体及其药物偶联物 | |
| WO2026077396A1 (fr) | Traitement du cancer pharmacorésistant à base de conjugué anticorps-médicament anti-ror1 | |
| WO2026077395A1 (fr) | Thérapie de combinaison impliquant un conjugué anticorps-médicament anti-ror1 | |
| RU2847195C1 (ru) | Способы конъюгации дильса-альдера | |
| CA3288951A1 (fr) | Anticorps anti-ror1 et conjugué anticorps-médicament associé | |
| HK40112252A (en) | Antibodies to pmel17 and conjugates thereof | |
| US20150152193A1 (en) | Axl antibodies | |
| WO2026057074A1 (fr) | Thérapie de combinaison avec un conjugué anticorps-médicament anti-liv-1 | |
| WO2025242039A1 (fr) | Anticorps anti-cdh17, conjugué anticorps-médicament associé et son utilisation | |
| HK40127994A (zh) | 抗cdh17抗体、其抗体药物偶联物及其用途 |